These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 33712515)

  • 1. Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    Pfeuffer S; Ruck T; Pul R; Rolfes L; Korsukewitz C; Pawlitzki M; Wildemann B; Klotz L; Kleinschnitz C; Scalfari A; Wiendl H; Meuth SG
    J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):1007-1013. PubMed ID: 33712515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Willis MD; Harding KE; Pickersgill TP; Wardle M; Pearson OR; Scolding NJ; Smee J; Robertson NP
    Mult Scler; 2016 Aug; 22(9):1215-23. PubMed ID: 26514979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
    Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
    Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
    Bose G; Rush C; Atkins HL; Freedman MS
    Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
    Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
    CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
    Zmira O; Halpern AI; Abraham L; Achiron A
    Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
    Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An additional analysis of the efficacy and safety of therapy in the Russian population of patients with multiple sclerosis participated in phase III international multicenter clinical trials: results of alemtuzumab study].
    Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):147-152. PubMed ID: 31935000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.